This article is about a non-clinically used progestin compound. For the pharmaceutical drug, see nomegestrol acetate.

Nomegestrol (INNTooltip International Nonproprietary Name), also known as 19-normegestrol, is a steroidal progestin which was patented in 1975 but was never marketed.[1][2] It is the parent compound of nomegestrol acetate, which is marketed as a progestin.[1][2]

Nomegestrol shows relatively low affinity for the progesterone receptor, only about 4% of that of progesterone and about 1.6% of that of nomegestrol acetate in one assay.[3]

See also

References

  1. ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 883–. ISBN 978-1-4757-2085-3.
  2. ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 747–. ISBN 978-3-88763-075-1.
  3. ^ Botella J, Duc I, Delansorne R, Paris J, Lahlou B (December 1990). "Structure-activity and structure-affinity relationships of 19-nor-progesterone derivatives in rat uterus". J. Endocrinol. Invest. 13 (11): 905–10. doi:10.1007/BF03349652. PMID 2090671. S2CID 37429648.